ZKSCAN1

ZKSCAN1 (ZNF139) is a zinc finger transcription factor that promotes gastric cancer cell survival, proliferation, invasion, and multi-drug resistance by coordinating the expression of apoptotic and drug-resistance gene programs (PMID:24515389, PMID:26722429, PMID:27698826). Loss-of-function studies establish that ZKSCAN1 maintains apoptosis resistance by sustaining anti-apoptotic effectors (Bcl-2, Survivin, xIAP) while restraining pro-apoptotic Bax and caspase-3, such that its depletion triggers G0/G1 arrest and apoptosis in vitro and reduces tumor growth in vivo (PMID:26722429, PMID:27698826). In parallel, ZKSCAN1 drives the multi-drug resistance phenotype by upregulating MDR1/P-gp and MRP1, with knockdown increasing chemosensitivity to 5-FU and L-OHP (PMID:24515389). One transcriptional mechanism is direct: ZKSCAN1 binds and represses the miR-185 promoter, and the resulting drop in miR-185 derepresses MDR1/P-gp, MRP-1, and Bcl-2, defining a ZNF139→miR-185 axis in drug resistance (PMID:30126848); ZKSCAN1 itself is held in check post-transcriptionally by miR-195-5p acting on its 3'-UTR (PMID:29956811). ZKSCAN1 also controls metastatic behavior by shifting the MMP-TIMP balance, promoting MMP-2/MMP-9 expression and gelatinase activity and ICAM-1 while suppressing TIMP-1 (PMID:24824930). Separately, ZKSCAN1 has been recovered as the 5' partner in oncogenic kinase fusions with MET in Spitz melanocytoma (PMID:40664441) and with BRAF [PMID:bio_10.1101_2025.02.06.636895].

1. 2014 Medium

   Established that ZKSCAN1 controls gastric cancer cell invasion and migration, identifying the MMP-TIMP axis as a downstream effector program rather than leaving its pro-metastatic role mechanistically unattributed.

   Evidence siRNA knockdown with wound healing, Transwell, RT-PCR, Western blot, and gelatin zymography in gastric cancer cells

   PMID:24824930

   Open questions at the time

   • Does not show ZKSCAN1 binds MMP-2/MMP-9 or TIMP-1 promoters directly
   • Single lab, single cancer type
   • No in vivo metastasis readout
2. 2014 Medium

   Linked ZKSCAN1 to the multi-drug resistance phenotype by showing its depletion lowers MDR1/P-gp, MRP1, and Bcl-2 and restores chemosensitivity, framing it as a regulator of drug-resistance gene expression.

   Evidence siRNA transfection with MTT chemosensitivity assay, RT-PCR, Western blot

   PMID:24515389

   Open questions at the time

   • Direct vs indirect transcriptional control of MDR genes not resolved here
   • No demonstration of promoter occupancy
   • Single lab
3. 2014 Low

   An unbiased proteomic screen broadened the candidate effector set downstream of ZKSCAN1, but established correlation rather than direct regulation.

   Evidence siRNA knockdown with 2-D DIGE and LC-MS proteomics, Western blot in BGC823 cells

   PMID:25436386

   Open questions at the time

   • Screen identifies downstream proteins without establishing direct regulatory mechanism
   • Functional consequence of each altered protein untested
   • Single study
4. 2015 Medium

   Resolved how ZKSCAN1 sustains survival by tying its loss to apoptosis and G0/G1 arrest through coordinated changes in Survivin, xIAP, Bcl-2, Bax, and caspase-3.

   Evidence siRNA knockdown with flow cytometry for cell cycle and apoptosis, QPCR, Western blot

   PMID:26722429

   Open questions at the time

   • Direct transcriptional targets among these apoptotic regulators not identified
   • Single cell line
   • No promoter-binding evidence
5. 2016 Medium

   Extended the survival role from culture to a tumor-bearing mouse model, confirming ZKSCAN1 promotes tumor growth via Bcl-2/survivin-dependent apoptosis suppression in vivo.

   Evidence siRNA knockdown with viability assays, Western blot, and in vivo mouse tumor model

   PMID:27698826

   Open questions at the time

   • Knockdown durability and specificity in vivo not fully controlled
   • Mechanism upstream of Bcl-2/survivin not addressed
   • Single lab
6. 2018 Medium

   Provided the first direct transcriptional mechanism for ZKSCAN1, showing it represses the miR-185 promoter to derepress MDR and anti-apoptotic genes, converting a correlative MDR role into a defined regulatory axis.

   Evidence ChIP and dual-luciferase reporter assays with siRNA/overexpression, MTT, RT-PCR, Western blot

   PMID:30126848

   Open questions at the time

   • Exact ZKSCAN1 binding site on miR-185 promoter not mapped
   • Whether miR-185 fully accounts for MDR phenotype unquantified
   • Single lab
7. 2018 Medium

   Placed ZKSCAN1 itself under upstream control by identifying miR-195-5p as a direct 3'-UTR regulator, situating it within a microRNA network governing chemoresistance.

   Evidence 3'-UTR luciferase reporter assay with Western blot, siRNA knockdown, MTT

   PMID:29956811

   Open questions at the time

   • Endogenous miR-195-5p regulation of ZKSCAN1 in patient tissue not shown
   • Single lab
8. 2025 Low

   Identified ZKSCAN1 as a structural fusion partner that can drive oncogenic kinase activation, distinct from its transcription-factor role, via a ZKSCAN1::MET fusion in Spitz melanocytoma.

   Evidence Next-generation sequencing / fusion detection on tumor tissue (single case report)

   PMID:40664441

   Open questions at the time

   • Single case report with no functional reconstitution of the fusion protein
   • Contribution of the ZKSCAN1 moiety to MET activation untested
   • No clinical follow-up of fusion-driven behavior
9. 2025 Low

   Showed that a ZKSCAN1::BRAF fusion signals in a fusion-dependent manner and exhibits paradoxical ERK activation resolvable by vertical RAF/MEK inhibition, indicating a therapeutically actionable kinase-fusion behavior.

   Evidence Overexpression of BRAF fusion constructs with ERK phosphorylation assays, inhibitor treatment, and tumor growth assay (preprint)

   PMID:bio_10.1101_2025.02.06.636895

   Open questions at the time

   • Preprint; ZKSCAN1 is only one of several fusion partners tested, so ZKSCAN1-specific contribution is limited
   • Endogenous occurrence of ZKSCAN1::BRAF not established
   • No structural basis for fusion-driven dimerization shown

• The direct genomic binding sites and full target repertoire of ZKSCAN1 as a transcription factor remain undefined, leaving open how it selects among apoptotic, MDR, and invasion gene programs.
• No genome-wide binding map (ChIP-seq) for ZKSCAN1
• Only miR-185 promoter shown as a direct target
• Mechanism of how the same factor coordinates survival, MDR, and invasion programs unknown